Systemic and intraperitoneal inflammation in peritoneal dialysis patients

Czech version

Authors: Sylvie Opatrná ^1,2
Authors‘ workplace: I. interní klinika LF v Plzni UK a FN Plzeň ¹; Biomedicínské centrum LF v Plzni UK ²
Published in: Vnitř Lék 2016; 62(Suppl 6): 58-61
Category: Reviews

Práce byla přednesena jako vyžádaná přednáška na 52. kongresu ERA-EDTA, 28.–31. května 2015, Londýn, Spojené království.

Overview

Any degree of microinflammation is an independent risk factor for mortality for patients with chronic kidney disease in all stages. During peritoneal dialysis, intraperitoneal activation of inflammation occurs, the degree of which in stable patients without infectious complications depends in particular on the content of peritoneal dialysis solution with regard to osmotic agents (glucose, icodextrin) and buffer (lactate, bicarbonate or their combination) which as the same time defines the level of biocompatibility of these solutions. The degree of intraperitoneal inflammation affects peritoneal permeability, however there is no evidence of it directly increasing the systemic inflammation and it does not correlate with mortality. On the other hand, the systemic inflammation affected in peritoneal dialysis patients primarily by age and comorbidities, i.e. factors independent of peritoneal dialysis alone, does predict long-term clinical results.

Key words:
biocompatibility – icodextrin – inflammation – peritoneal dialysis – peritoneal dialysis solutions

Sources

1. Stenvinkel P. Inflammation in end-stage renal disease: A fire that burns within. Contrib Nephrol 2005; 149: 185–199.

2. Meuwese CL, Snaedal S, Halbesma N et al. Trimetral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-alfa are similarly associated with survival in haemodialysis patients. Nephrol Dial Transplant 2011; 26(4): 1313–1318. Dostupné z DOI: <http://dx.doi.org/10.1093/ndt/gfq557>.

3. Zhang W, Hej, Zhang F et al. Prognostic role of C-reactive protein and interleukin-6 in dialysis patients: a systematic review and meta-analysis. J Nephrol 2013; 26(2): 243–253. Dostupné z DOI: <http://dx.doi.org/10.5301/jn.5000169>.

4. Yuan J, Guo Q, Qureshi AR et al. Circulating vascular endothelial growth factor (VEGF) and its soluble receptor 1 (SVEGFR-1) are associated with inflammation and mortality in incident dialysis patients. Nephrol Dial Transplant 2013; 28(9): 2356–2363. Dostupné z DOI: <http://dx.doi.org/10.1093/ndt/gft256>.

5. Pecoits-Filho R, Barany P, Lindholm B et al. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002; 17(9): 1684–1688.

6. Cho Y, Johnson DW, Vesey DA et al. Baseline serum interleukon-6 predicts cardiovascular events in incident peritoneal dialysis patients. Perit Dial Int 2015; 35(1): 35–42. Dostupné z DOI: <http://dx.doi.org/10.3747/pdi.2013.00272>.

7. Zebrack JS, Anderson JL, Beddhu S et al. Do associations with C-reactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal insufficiency? J Am Coll Cardiol 2003; 42(1): 57–63.

8. Menon V, Gul A, Sarnak MG. Cardiovascular risk factors in chronic kidney disease. Kidney Int 2005; 68(4): 1413–1418.

9. Bemelmans MH, Gouma DJ, Buurman WA. Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol 1993; 150(5): 2007–2017.

10. Poole S, Bird TA, Selkirk S et al. Fate of injected interleukin 1 in rats: sequestration and degradation in the kidney. Cytokine 1990; 2(6): 416–422.

11. Panichi V, Migliori M, De Pietro S et al. C reactive protein in patients with chronic renal diseases. Ren Fail 2001; 23(3–4): 551–562.

12. Opatrná S, Klaboch J, Opatrný K jr et al. Procalcitonin levels in peritoneal dialysis patients. Perit Dial Int 2005; 25(5): 470–472.

13. Guessous I, Ponte B, Marques-Vidal P et al. Clinical and biological determinants of kidney outcomes in a population-based kohort study. Kidney Blood Press Res 2014; 39(1): 74–85. Dostupné z DOI: <http://dx.doi.org/10.1159/000355779>.

14. Shi K, Wang F, Jiang H et al. Gut bacterial translocation may aggravate microinflammation in hemodialysis patients. Dig Dis Sci 2014; 59(9): 2109–2117. Dostupné z DOI: <http://dx.doi.org/10.1007/s10620–014–3202–7>.

15. McIntyre CW, Harrison LE, Eldehni MT et al. Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6(1): 133–141. Dostupné z DOI: <http://dx.doi.org/10.2215/CJN.04610510>.

16. Himmelfarb J, Stenvinkel P, Ikizler TA et al. The elephant in uremia: oxidant stress as a unifying koncept of cardiovascular disease in uremia. Kidney Int 2002; 62(5): 1524–1538.

17. Kalantar-Zadeh K, Kopple JD, Deepak S et al. Food intake characteristics of hemodialysis patients as obtained by food frequency questionnaire. J Ren Nutr 2002; 12(1): 17–31.

18. Suliman ME, Heimburger O, Barany P et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol 2003; 14(6): 1614–1622.

19. Paříková A. Ultrafiltrace a prevence alterace peritoneální membrány – determinanty úspěšnosti léčby peritoneální dialýzou. Vnitř Lék 2008; 54(12): 1127–1128.

20. Zemel D, Imholz ALT, de Waart DR et al. Appearance of tumor necrosis factor-alfa and soluble TNF-receptors I and II in peritoneal effluent of CAPD. Kidney Int 1994; 46(5): 1422–1430.

21. Lai KN, Lai KB, Chan TM et al. Changes of cytokine profile during peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2000; 35(4): 644–652.

22. Flessner MF, Credit K, Richardson K et al. Peritoneal inflammation after twenty-week exposure to dialysis solution: effect of solution versus catheter-foreign body reaction. Perit Dial Int 2010; 30(3): 284–293. Dostupné z DOI: <http://dx.doi.org/10.3747/pdi.2009.00100>.

23. Paniague R, Ventura de Jesus M, Rodriguez E et al. Impact of fill volume on peritoneal clearances and cytokine appearance in peritoneal dialysis. Perit Dial Int 2004; 24(2): 156–162.

24. Cooker L, Luneburg P, Holmes CJ et al. Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions. Perit Dial Int 2001; 21(Suppl 3): S102-S107.

25. Klaboch J, Opatrná S, Matoušovic K et al. Konečné stadium chronického onemocnění ledvin a metabolická acidóza. Vnitř Lék 2012; 58(7–8): 519–524.

26. Pajek J, Kveder R, Bren A et al. Short-term effects of a new bicarbonate/lactate-buffered and conventional peritoneal dialysis fluid on peritoneal and systemic inflammation in CAPD patients: a randomized controlled study. Perit Dial Int 2008; 28(1): 44–52.

27. Weiss L, Stegmayr B, Malmsten G et al. Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int 2009; 29(6): 647–655.

28. Wolfson M, Piraino B, Hamburger RJ et al. [Icodextrin Study Group]. A randomized controlled trial to evaluace the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 2002; 40(5): 1055–1065.

29. Mistry CD, Mallick NP, Gokal R. Ultrafiltration with isosmotic solution during long peritoneal dialysis exchanges. Lancet 1987; 2(8552): 178–182.

30. Parikova A, Zweers MM, Struijk DG et al. Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions. Adv Perit Dial 2003; 19: 186–190.

31. Martikainen T, Teppo AM, Gronhagen-Riska C et al. Glucose-free dialysis solutions: inductors of an inflammation or preservers of peritoneal membrane? Perit Dial Int 2005; 25(5): 453–460.

32. Moriishi M, Kawanishi H. Icodextrin and intraperitoneal inflammation. Perit Dial Int 2008; 28(Suppl 3): S96-S100.

33. Opatrná S, Lysák D, Trefil L et al. Intraperitoneal IL-6 signaling in incident patients treated with icodextrin and glucose bicarbonate/lactate-based peritoneal dialysis solutions. Perit Dial Int 2012; 32(1): 37–44.Dostupné z DOI: <http://dx.doi.org/10.3747/pdi.2010.00235>.

34. Poole CY, Welten AG, Wee PM et al. A peritoneal dialysis regimen low in glucose and glucose degradation products results in increased cancer antigen 125 and peritoneal activation. Perit Dial Int 2012; 32(3): 305–315. Dostupné z DOI: <http://dx.doi.org/10.3747/pdi.2010.00115>.

35. Pecoits-Filho R, Carvalho MJ, Stenvinkel P et al. Systemic and intraperitoneal IL-6 system during the first year of peritoneal dialysis. Perit Dial Int 2006; 26(1): 53–63.

36. Opatrná S, Popperlová A, Lysák D et al. Effects of icodexstrin and glucose bicarbonate /lactate buffered peritoneal dialysis fluids on effluent cell population and biocompatibility markers IL-6 and CA125 in incident peritoneal dialysis patients. Ther Apher Dial 2016; 20(2): 149–157. Dostupné z DOI: <http://dx.doi.org/10.1111/1744–9987.12391>.

37. Lambie M, Chess J, Donovan KL et al. Independent Effects of Systemic and Peritoneal Inflammation on Peritoneal Dialysis Survival. J Am Soc Nephrol 2013; 24(12): 2071–2080. Dostupné z DOI: <http://dx.doi.org/10.1681/ASN.2013030314>.

38. Opatrná S. Icodextrinový peritoneální dialyzační roztok v klinické praxi. Vnitř Lék 2008; 54(12): 1155–1160.